References
- Fitzmaurice C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. JAMA Oncol. 2017;3:524–548.
- Miyauchi S, Kim SS, Pang J, et al. Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. Clin Cancer Res. 2019;25(14):4211–4223.
- Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52:228–240.
- Pai S, Bamodu OA, Lin Y-K, et al. CD47-SIRPα signaling induces epithelial-mesenchymal transition and cancer stemness and links to a poor prognosis in patients with oral squamous cell carcinoma. Cells. 2019;8(12):1658.
- Rampino M, et al. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Res. 2012;32:195–199.
- Auluck A, et al. Trends in oropharyngeal and oral cavity cancer incidence of Human Papillomavirus (HPV)-related and HPV-unrelated sites in a multicultural population: the British Columbia experience. Cancer. 2010;116:2635–2644.
- Brown CE, Lechner T, Howe LA, et al. The many HATs of transcription coactivators. Trends Biochem Sci. 2000;25(1):15–19.
- Wang YL, Faiola F, Xu M, et al. Human ATAC is a GCN5/PCAF-containing acetylase complex with a novel NC2-like histone fold module that interacts with the TATA-binding protein. J Biol Chem. 2008;283(49):33808–33815.
- Zhao D, Guan H, Zhao S, et al. YEATS2 is a selective histone crotonylation reader. Cell Res. 2016;26(5):629–632.
- Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386–396.
- Mi W, Guan H, Lyu J, et al. YEATS2 links histone acetylation to tumorigenesis of non-small cell lung cancer. Nat Commun. 2017;8(1):1088.
- Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203–221.
- Mollaei H, Safaralizadeh R, Rostami Z. MicroRNA replacement therapy in cancer. J Cell Physiol. 2019;234(8):12369–12384.
- Wang L, Ge S, Zhou F. MicroRNA-487a-3p inhibits the growth and invasiveness of oral squamous cell carcinoma by targeting PPM1A. Bioengineered. 2021;12(1):937–947.
- Zhang L, Liao Y, Tang L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. J Exp Clin Cancer Res. 2019;38(1):53.
- Zheng S, Li M, Miao K, et al. lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J Cell Biochem. 2020;121(3):2225–2235.
- Li K, Zhang J, Zhang M, et al. miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1. World J Surg Oncol. 2021;19(1):54.
- Pan X, et al. MiR-378a-5p acts as a tumor suppressor in renal cell carcinoma and is associated with the good prognosis of patients. Am J Transl Res. 2019;11:2207–2218.
- Tupone MG, D’Aguanno S, Di Martile M, et al. microRNA-378a-5p is a novel positive regulator of melanoma progression. Oncogenesis. 2012;9(2):22.
- Cui Z, Liu QL, Sun SQ, et al. MiR-378a-5p inhibits angiogenesis of oral squamous cell carcinoma by targeting KLK4. Neoplasma. 2020;67(1):85–92.
- Mu L, Yang F, Guo D, et al. Overexpression of secretory clusterin (sCLU) induces chemotherapy resistance in human gastric cancer cells by targeting miR-195-5p. Bioengineered. 2020;11(1):472–483.
- Geng X, Sun Y, Fu J, et al. MicroRNA-17-5p inhibits thyroid cancer progression by suppressing Early growth response 2 (EGR2). Bioengineered. 2021;12(1):2713–2722.
- Zeng Z, Lei S, He Z, et al. YEATS2 is a target of HIF1α and promotes pancreatic cancer cell proliferation and migration. J Cell Physiol. 2021;236(3):2087–2098.
- Zeng W, Guo M, Yao L, et al. Circular RNA hsa_circ_0033144 (CircBCL11B) regulates oral squamous cell carcinoma progression via the miR-579/LASP1 axis. Bioengineered. 2021;12(1):4111–4122.
- Suhail Y, et al. Systems biology of cancer metastasis. Cell Syst. 2019;9:109–127.
- Ku WT, Tung JJ, Lee TJF, et al. Long-term exposure to oroxylin a inhibits metastasis by suppressing CCL2 in oral squamous cell carcinoma cells. Cancers (Basel). 2019;11(3):353.
- Lengyel E, Schmalfeldt B, Konik E, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001;82(2):291–298.
- Chiang WF, Hwang T-Z, Hour T-C, et al. Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol. 2013;49(6):534–541.
- Wang SS, Zheng M, Pang X, et al. Macrophage migration inhibitory factor promotes the invasion and metastasis of oral squamous cell carcinoma through matrix metalloprotein-2/9. Mol Carcinog. 2019;58(10):1809–1821.
- Liu H, Zeng Z, Wang S, et al. Main components of pomegranate, ellagic acid and luteolin, inhibit metastasis of ovarian cancer by down-regulating MMP2 and MMP9. Cancer Biol Ther. 2017;18(12):990–999.
- Tian S, Peng P, Li J, et al. SERPINH1 regulates EMT and gastric cancer metastasis via the Wnt/β-catenin signaling pathway. Aging (Albany NY). 2020;12(4):3574–3593.
- Wang J, Cai H, Liu Q, et al. Cinobufacini inhibits colon cancer invasion and metastasis via suppressing Wnt/β-Catenin signaling pathway and EMT. Am J Chin Med. 2020;48(3):703–718.